Navigation Links
Varian Medical Systems Spotlights Fully Integrated Intensity Modulated Proton Therapy at PTCOG 2011 Meeting
Date:5/6/2011

PHILADELPHIA, May 6, 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) is highlighting its ProBeam™ proton therapy system and Eclipse™ treatment planning capabilities at the 2011 PTCOG meeting here from May 8th-14th .

"Intensity modulated proton therapy (IMPT) is the new frontier in proton therapy and has the potential to improve dose distributions in the same fashion that IMRT did for conventional X-ray radiotherapy," says Moataz Karmalawy, head of Varian's particle therapy group. "This means getting closer to the radiation therapy treatment goal of applying optimum dose to the cancerous tumour while sparing healthy tissue and organs at risk that lie in the beam's path."

"IMPT requires the integration of smart treatment planning and precise pencil beam scanning delivery," adds Karmalawy. "We've achieved that by teaming up our market-leading Eclipse treatment planning software with our ProBeam delivery system." Eclipse recently received FDA 510(k) clearance for use with Varian's IMPT delivery systems in the U.S.

The goal of IMPT is to shape the dose distribution so that it matches the shape of the targeted tumor in all three dimensions.  An important feature of the latest Eclipse release is the ability to analyze the robustness of a treatment plan in terms of its ability to optimally cover the tumor and reduce dose to healthy tissues.  "IMPT is especially beneficial for complex tumor shapes, such as head-and-neck tumors, tumors of the lower abdomen that have a curved shape, and tumors wrapped around the spinal cord or brain stem," says Karmalawy.

Varian's ProBeam system incorporates pencil-beam scanning technology, which optimizes the dose applied to every point within the area being treated. Several new ProBeam features will be demonstrated in the Varian booth, including a new user interface, a more compact robotic patient positioner and advanced imaging capabilities for precise patient setup verification and correction utilizing planar imaging and 3D kV cone CT imaging.

"With the introduction of pencil beam scanning, the workflow of proton therapy has already become significantly more efficient," says Karmalawy. "The introduction of the new user interface, the patient positioner and imaging enhancements make this system easier to use for clinicians, building on our workflow expertise in conventional radiotherapy."

Varian has equipped the Rinecker Proton Therapy Centre (RPTC) in Munich, site of the world's first clinical IMPT treatments. Construction work is currently underway at the Scripps Proton Therapy Center in San Diego, which will also be equipped with Varian hardware and software. The company has also been named preferred supplier for a number of other proton therapy ventures globally.

"Varian is entirely committed to proton therapy and brings the same integrated, automated and versatile approach to protons as it has for many years of leadership in radiation therapy," says Lester Boeh, head of Varian's emerging businesses group.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,500 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/27/2016)... Dublin, CA (PRWEB) , ... June 27, 2016 ... ... Community College District , the only authorized OSHA Training Institute Education Center headquartered ... illness by protecting their workers from extreme heat at their worksites. Employers ...
(Date:6/27/2016)... ... , ... "FCPX editors can now reveal their media with growing colorful split ... Austin - CEO of Pixel Film Studios. , ProSlice Color brings the split ... now reveal the media of their split screens with growing colorful panels. , ProSlice ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
Breaking Medicine News(10 mins):